Veronica Steri, PhD

Title(s)Specialist, HDF Comprehensive Cancer Ctr
SchoolSchool of Medicine
Address1450 Third Street, #001
San Francisco CA 94158
Phone415-214-2390
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    UEA, Norwich (UK)PhD2015Tumor Angiogenesis
    Alma Mater Studiorum, Bologna (IT)Habilitation2008Biology
    Alma Mater Studiorum, Bologna (IT)Master2007Medical Biotechnology
    Alma Mater Studiorum, Bologna (IT)Bachelor2004Biotechnology
    Collapse Awards and Honors
    EACR2013Travel Fellowship Award
    BSCB2012Honor Fell / Company of Biologists Travel Awards
    Sapienza University (Rome)2007Unipharma-Graduates Project 3

    Collapse Overview 
    Collapse Overview
    I am an experienced Research Scientist skilled in Preclinical Tumor Models and in vivo Imaging. I received my education in Italy (Master Degree in Biotechnology) and UK (PhD in Biomolecular Science). After post-doctoral training at UCSF, I joined the UCSF Preclinical Therapeutics core in 2018 and I have been appointed PTC Manager in 2021. In this role, I run a lab that conducts preclinical oncology trials for UCSF Comprehensive Cancer Center investigators.

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Chemoproteomics reveals immunogenic and tumor-associated cell surface substrates of ectokinase CK2α. bioRxiv. 2024 Mar 20. Delaveris CS, Kong S, Glasgow J, Loudermilk RP, Kirkemo LL, Zhao F, Salangsang F, Phojanakong P, Camara Serrano JA, Steri V, Wells JA. PMID: 38562834; PMCID: PMC10983885.
      View in: PubMed   Mentions:
    2. CD46-Targeted Theranostics for PET and 225Ac-Radiopharmaceutical Therapy of Multiple Myeloma. Clin Cancer Res. 2024 03 01; 30(5):1009-1021. Wadhwa A, Wang S, Patiño-Escobar B, Bidkar AP, Bobba KN, Chan E, Meher N, Bidlingmaier S, Su Y, Dhrona S, Geng H, Sarin V, VanBrocklin HF, Wilson DM, He J, Zhang L, Steri V, Wong SW, Martin TG, Seo Y, Liu B, Wiita AP, Flavell RR. PMID: 38109209; PMCID: PMC10905524.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimalsCells
    3. Targeting high-risk multiple myeloma genotypes with optimized anti-CD70 CAR-T cells. bioRxiv. 2024 Feb 28. Kasap C, Izgutdina A, Patiño-Escobar B, Kang A, Chilakapati N, Akagi N, Johnson H, Rashid T, Werner J, Barpanda A, Geng H, Lin YT, Rampersaud S, Gil-Alós D, Sobh A, Dupéré-Richer D, Wicaksono G, Kawehi Kelii KM, Dalal R, Ramos E, Vijayanarayanan A, Salangsang F, Phojanakong P, Serrano JAC, Zakraoui O, Tariq I, Steri V, Shanmugam M, Boise LH, Kortemme T, Stieglitz E, Licht JD, Karlon WJ, Barwick BG, Wiita AP. PMID: 38463958; PMCID: PMC10925123.
      View in: PubMed   Mentions:
    4. Framework humanization optimizes potency of anti-CD72 nanobody CAR-T cells for B-cell malignancies. J Immunother Cancer. 2023 11 24; 11(11). Temple WC, Nix MA, Naik A, Izgutdina A, Huang BJ, Wicaksono G, Phojanakong P, Serrano JAC, Young EP, Ramos E, Salangsang F, Steri V, Xirenayi S, Hermiston M, Logan AC, Stieglitz E, Wiita AP. PMID: 38007238; PMCID: PMC10680002.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCells
    5. Allosteric SHP2 inhibition increases apoptotic dependency on BCL2 and synergizes with venetoclax in FLT3- and KIT-mutant AML. Cell Rep Med. 2023 11 21; 4(11):101290. Popescu B, Stahlhut C, Tarver TC, Wishner S, Lee BJ, Peretz CAC, Luck C, Phojanakong P, Camara Serrano JA, Hongo H, Rivera JM, Xirenayi S, Chukinas JA, Steri V, Tasian SK, Stieglitz E, Smith CC. PMID: 37992684; PMCID: PMC10694768.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    6. Structural surfaceomics reveals an AML-specific conformation of integrin β2 as a CAR T cellular therapy target. Nat Cancer. 2023 Nov; 4(11):1592-1609. Mandal K, Wicaksono G, Yu C, Adams JJ, Hoopmann MR, Temple WC, Izgutdina A, Escobar BP, Gorelik M, Ihling CH, Nix MA, Naik A, Xie WH, Hübner J, Rollins LA, Reid SM, Ramos E, Kasap C, Steri V, Serrano JAC, Salangsang F, Phojanakong P, McMillan M, Gavallos V, Leavitt AD, Logan AC, Rooney CM, Eyquem J, Sinz A, Huang BJ, Stieglitz E, Smith CC, Moritz RL, Sidhu SS, Huang L, Wiita AP. PMID: 37904046; PMCID: PMC10663162.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    7. Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer. Cancer Res. 2023 01 18; 83(2):301-315. Chou J, Egusa EA, Wang S, Badura ML, Lee F, Bidkar AP, Zhu J, Shenoy T, Trepka K, Robinson TM, Steri V, Huang J, Wang Y, Small EJ, Chan E, Stohr BA, Ashworth A, Delafontaine B, Rottey S, Cooke KS, Hashemi Sadraei N, Yu B, Salvati M, Bailis JM, Feng FY, Flavell RR, Aggarwal R. PMID: 36351060; PMCID: PMC10263373.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimals
    8. Comparison and calibration of dose delivered by137Cs and x-ray irradiators in mice. Phys Med Biol. 2022 11 18; 67(22). Caravaca J, Peter R, Yang J, Gunther C, Antonio Camara Serrano J, Nostrand C, Steri V, Seo Y. PMID: 36317316; PMCID: PMC9933773.
      View in: PubMed   Mentions:    Fields:    Translation:Animals
    9. Modular cytokine receptor-targeting chimeras for targeted degradation of cell surface and extracellular proteins. Nat Biotechnol. 2023 02; 41(2):273-281. Pance K, Gramespacher JA, Byrnes JR, Salangsang F, Serrano JC, Cotton AD, Steri V, Wells JA. PMID: 36138170; PMCID: PMC9931583.
      View in: PubMed   Mentions: 23     Fields:    Translation:Cells
    10. A covalent inhibitor of K-Ras(G12C) induces MHC class I presentation of haptenated peptide neoepitopes targetable by immunotherapy. Cancer Cell. 2022 09 12; 40(9):1060-1069.e7. Zhang Z, Rohweder PJ, Ongpipattanakul C, Basu K, Bohn MF, Dugan EJ, Steri V, Hann B, Shokat KM, Craik CS. PMID: 36099883; PMCID: PMC10393267.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    11. Extensive conformational and physical plasticity protects HER2-HER3 tumorigenic signaling. Cell Rep. 2022 Sep 06; 40(10):111338. Campbell MR, Ruiz-Saenz A, Zhang Y, Peterson E, Steri V, Oeffinger J, Sampang M, Jura N, Moasser MM. PMID: 36070686; PMCID: PMC9484489.
      View in: PubMed   Mentions:    Fields:    
    12. Allosteric HSP70 inhibitors perturb mitochondrial proteostasis and overcome proteasome inhibitor resistance in multiple myeloma. Cell Chem Biol. 2022 08 18; 29(8):1288-1302.e7. Ferguson ID, Lin YT, Lam C, Shao H, Tharp KM, Hale M, Kasap C, Mariano MC, Kishishita A, Patiño Escobar B, Mandal K, Steri V, Wang D, Phojanakong P, Tuomivaara ST, Hann B, Driessen C, Van Ness B, Gestwicki JE, Wiita AP. PMID: 35853457; PMCID: PMC9434701.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    13. Targeting a proteolytic neoepitope on CUB domain containing protein 1 (CDCP1) for RAS-driven cancers. J Clin Invest. 2022 02 15; 132(4). Lim SA, Zhou J, Martinko AJ, Wang YH, Filippova EV, Steri V, Wang D, Remesh SG, Liu J, Hann B, Kossiakoff AA, Evans MJ, Leung KK, Wells JA. PMID: 35166238; PMCID: PMC8843743.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansAnimalsCells
    14. Targetable HER3 functions driving tumorigenic signaling in HER2-amplified cancers. Cell Rep. 2022 02 01; 38(5):110291. Campbell MR, Ruiz-Saenz A, Peterson E, Agnew C, Ayaz P, Garfinkle S, Littlefield P, Steri V, Oeffinger J, Sampang M, Shan Y, Shaw DE, Jura N, Moasser MM. PMID: 35108525; PMCID: PMC8889928.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    15. Extensive conformational and physical plasticity protects HER2-HER3 tumorigenic signaling. Cell Rep. 2022 02 01; 38(5):110285. Campbell MR, Ruiz-Saenz A, Zhang Y, Peterson E, Steri V, Oeffinger J, Sampang M, Jura N, Moasser MM. PMID: 35108526; PMCID: PMC8865943.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    16. Targeting a splicing-mediated drug resistance mechanism in prostate cancer by inhibiting transcriptional regulation by PKCβ1. Oncogene. 2022 03; 41(11):1536-1549. Melnyk JE, Steri V, Nguyen HG, Hwang YC, Gordan JD, Hann B, Feng FY, Shokat KM. PMID: 35087237; PMCID: PMC8913362.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    17. The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers. Sci Rep. 2021 04 27; 11(1):9091. Majumder A, Sandhu M, Banerji D, Steri V, Olshen A, Moasser MM. PMID: 33907275; PMCID: PMC8079373.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansAnimalsCells
    18. Surface Proteomics Reveals CD72 as a Target for In Vitro-Evolved Nanobody-Based CAR-T Cells in KMT2A/MLL1-Rearranged B-ALL. Cancer Discov. 2021 08; 11(8):2032-2049. Nix MA, Mandal K, Geng H, Paranjape N, Lin YT, Rivera JM, Marcoulis M, White KL, Whitman JD, Bapat SP, Parker KR, Ramirez J, Deucher A, Phojanokong P, Steri V, Fattahi F, Hann BC, Satpathy AT, Manglik A, Stieglitz E, Wiita AP. PMID: 33727310; PMCID: PMC8338785.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    19. Transit-Amplifying Cells Coordinate Changes in Intestinal Epithelial Cell-Type Composition. Dev Cell. 2021 02 08; 56(3):356-365.e9. Sanman LE, Chen IW, Bieber JM, Steri V, Trentesaux C, Hann B, Klein OD, Wu LF, Altschuler SJ. PMID: 33484640; PMCID: PMC7917018.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansAnimalsCells
    20. The splicing modulator sulfonamide indisulam reduces AR-V7 in prostate cancer cells. Bioorg Med Chem. 2020 10 15; 28(20):115712. Melnyk JE, Steri V, Nguyen HG, Hann B, Feng FY, Shokat KM. PMID: 33069070.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimalsCells
    21. Systematic identification of engineered methionines and oxaziridines for efficient, stable, and site-specific antibody bioconjugation. Proc Natl Acad Sci U S A. 2020 03 17; 117(11):5733-5740. Elledge SK, Tran HL, Christian AH, Steri V, Hann B, Toste FD, Chang CJ, Wells JA. PMID: 32123103; PMCID: PMC7084160.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansAnimalsCells
    22. KRASG12C inhibition produces a driver-limited state revealing collateral dependencies. Sci Signal. 2019 05 28; 12(583). Lou K, Steri V, Ge AY, Hwang YC, Yogodzinski CH, Shkedi AR, Choi ALM, Mitchell DC, Swaney DL, Hann B, Gordan JD, Shokat KM, Gilbert LA. PMID: 31138768; PMCID: PMC6871662.
      View in: PubMed   Mentions: 72     Fields:    Translation:HumansAnimalsCells
    23. HER2 Amplification in Tumors Activates PI3K/Akt Signaling Independent of HER3. Cancer Res. 2018 07 01; 78(13):3645-3658. Ruiz-Saenz A, Dreyer C, Campbell MR, Steri V, Gulizia N, Moasser MM. PMID: 29760043; PMCID: PMC6779043.
      View in: PubMed   Mentions: 61     Fields:    Translation:HumansAnimalsCells
    24. Vascular targeting of LIGHT normalizes blood vessels in primary brain cancer and induces intratumoural high endothelial venules. J Pathol. 2018 06; 245(2):209-221. He B, Jabouille A, Steri V, Johansson-Percival A, Michael IP, Kotamraju VR, Junckerstorff R, Nowak AK, Hamzah J, Lee G, Bergers G, Ganss R. PMID: 29603739; PMCID: PMC6737176.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansAnimalsCells
    25. Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation. Sci Transl Med. 2017 04 12; 9(385). Allen E, Jabouille A, Rivera LB, Lodewijckx I, Missiaen R, Steri V, Feyen K, Tawney J, Hanahan D, Michael IP, Bergers G. PMID: 28404866; PMCID: PMC5554432.
      View in: PubMed   Mentions: 338     Fields:    Translation:AnimalsCells
    26. Antagonizing Integrin β3 Increases Immunosuppression in Cancer. Cancer Res. 2016 06 15; 76(12):3484-95. Su X, Esser AK, Amend SR, Xiang J, Xu Y, Ross MH, Fox GC, Kobayashi T, Steri V, Roomp K, Fontana F, Hurchla MA, Knolhoff BL, Meyer MA, Morgan EA, Tomasson JC, Novack JS, Zou W, Faccio R, Novack DV, Robinson SD, Teitelbaum SL, DeNardo DG, Schneider JG, Weilbaecher KN. PMID: 27216180; PMCID: PMC4944657.
      View in: PubMed   Mentions: 42     Fields:    Translation:AnimalsCells
    27. Suppression of β3-integrin in mice triggers a neuropilin-1-dependent change in focal adhesion remodelling that can be targeted to block pathological angiogenesis. Dis Model Mech. 2015 Sep; 8(9):1105-19. Ellison TS, Atkinson SJ, Steri V, Kirkup BM, Preedy ME, Johnson RT, Ruhrberg C, Edwards DR, Schneider JG, Weilbaecher K, Robinson SD. PMID: 26159543; PMCID: PMC4582102.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansAnimalsCells
    28. Redefining the role(s) of endothelial αvβ3-integrin in angiogenesis. Biochem Soc Trans. 2014 Dec; 42(6):1590-5. Atkinson SJ, Ellison TS, Steri V, Gould E, Robinson SD. PMID: 25399575.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    29. Acute depletion of endothelial β3-integrin transiently inhibits tumor growth and angiogenesis in mice. Circ Res. 2014 Jan 03; 114(1):79-91. Steri V, Ellison TS, Gontarczyk AM, Weilbaecher K, Schneider JG, Edwards D, Fruttiger M, Hodivala-Dilke KM, Robinson SD. PMID: 24103390.
      View in: PubMed   Mentions: 21     Fields:    Translation:AnimalsCells
    30. Fast track biopsy method: a rapid approach to preoperative diagnoses. Pathologica. 2010 Apr; 102(2):41-5. Steri V, Farnedi A, Montinari E, Foschini MP. PMID: 23596755.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    31. Regulation of dendritic cell migration by CD74, the MHC class II-associated invariant chain. Science. 2008 Dec 12; 322(5908):1705-10. Faure-André G, Vargas P, Yuseff MI, Heuzé M, Diaz J, Lankar D, Steri V, Manry J, Hugues S, Vascotto F, Boulanger J, Raposo G, Bono MR, Rosemblatt M, Piel M, Lennon-Duménil AM. PMID: 19074353.
      View in: PubMed   Mentions: 116     Fields:    Translation:AnimalsCells
    32. Functional specialization of human circulating CD16 and CD1c myeloid dendritic-cell subsets. Blood. 2007 Jun 15; 109(12):5371-9. Piccioli D, Tavarini S, Borgogni E, Steri V, Nuti S, Sammicheli C, Bardelli M, Montagna D, Locatelli F, Wack A. PMID: 17332250.
      View in: PubMed   Mentions: 91     Fields:    Translation:HumansCells
    33. AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 1245. Abstract 1245: RRx-001 is effective in temozolomide-sensitive and resistant GBM. Steri V., Oronsky B., Scicinski J, Bergers B. View Publication.
    Veronica's Networks
    Concepts (201)
    Derived automatically from this person's publications.
    _
    Co-Authors (61)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _